Cargando…
EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
Since the discovery of the fusion between EML4 (echinoderm microtubule associated protein-like 4) and ALK (anaplastic lymphoma kinase), EML4-ALK, in lung adenocarcinomas in 2007, and the subsequent identification of at least 15 different variants in lung cancers, there has been a revolution in molec...
Autores principales: | Sabir, Sarah R., Yeoh, Sharon, Jackson, George, Bayliss, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615333/ https://www.ncbi.nlm.nih.gov/pubmed/28872581 http://dx.doi.org/10.3390/cancers9090118 |
Ejemplares similares
-
Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
por: Papageorgiou, Savvas, et al.
Publicado: (2022) -
Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs
por: Bayliss, Richard, et al.
Publicado: (2016) -
A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC
por: Sampson, Josephina, et al.
Publicado: (2022) -
EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveries
por: Elshatlawy, Mariam, et al.
Publicado: (2023) -
Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)